Risk of docetaxel-induced peripheral neuropathy among 1,725 Danish patients with early stage breast cancer
- 17 October 2013
- journal article
- clinical trial
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 142 (1) , 109-118
Abstract
Docetaxel-induced peripheral neuropathy (PN) can lead to sub-optimal treatment in women with early breast cancer. Here, we compare the frequency of dose reduction as a result of PN in two different adjuvant regimens. From the Danish Breast Cancer Cooperative Group READ trial we included 1,725 patients with early stage breast cancer who randomly were assigned to three cycles of epirubicin and cyclophosphamide followed by three cycles docetaxel (D100) or six cycles of cyclophosphamide and docetaxel (D75). Eligible patients completed chemotherapy, received docetaxel, and provided information on patient-reported outcome (secondary outcome of trial) including PN. Associations between PN and risk factors were analyzed by multivariate logistic regression. Overall 597 patients (34 %) reported PN, grades 2–4, during treatment, 194 (11 %) after the first cycle [early onset peripheral neuropathy (EPN)] and 403 (23 %) after subsequent cycles [later-onset peripheral neuropathy (LPN)]. The odds ratio (OR) of EPN was significantly increased for the D100 regimen (OR 3.10; 95 % CI 2.18–4.42) while this regimen was associated with reduced OR of LPN (OR 0.69; 95 % CI 0.54–0.88). Patients with PN received significantly lower cumulative doses of docetaxel than patients with no PN. Explorative analysis showed that OR of PN was significantly reduced if patients wore frozen gloves and socks during treatment (OR 0.56; 95 % CI 0.38–0.81) in the EPN group. Patients developing PN after the first cycle are less likely to receive docetaxel at the planned dose intensity and usage of frozen gloves and socks may modify the risk.Keywords
This publication has 45 references indexed in Scilit:
- Taxane-induced nail changes: Predictors and efficacy of the use of frozen gloves and socks in the prevention of nail toxicityEuropean Journal of Oncology Nursing, 2012
- Chemotherapy-induced peripheral neurotoxicity (CIPN): An updateCritical Reviews in Oncology/Hematology, 2012
- Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trialThe Lancet Oncology, 2010
- Background NoiseNursing Research, 2007
- Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based studyThe Lancet Oncology, 2006
- Benefit of taxanes as adjuvant chemotherapy for early breast cancerCancer, 2006
- Symptom, Symptom Experiences, and Symptom Distress Encountered by Women With Breast Cancer Undergoing Current Treatment ModalitiesCancer Nursing, 2005
- Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy?Supportive Care in Cancer, 2005
- Weekly, high‐dose paclitaxel in advanced lung carcinomaCancer, 2003
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987